Spesolimab Decreases Generalized Pustular Psoriasis (GPP) Body Surface Area (BSA) over Time in Patients With Various Lengths of Disease History: Results from the EFFISAYIL® 2 Trial. J of Skin 2024, 8 (6), s489. https://doi.org/10.25251/skin.8.supp.489.